SVB shock could have chilling effect on British biotech sector
UK deal averted disaster for biotech start-ups
Some 40% of UK biotech firms were banking with SVB
UK aims to be life sciences "superpower"
Adds details about UK biotech that was exposed to SVB
By Natalie Grover and Maggie Fick
LONDON, March 13 (Reuters) -HSBC HSBA.L's rescue of the British arm of Silicon Valley Bank saved the heavily-exposed UK biotech sector from collapse, but the fallout could hamper funding in a sector the government sees as key to future economic growth, industry executives said.
The move brought an end to frantic weekend talks between the British government, regulators, and prospective buyers, as the survival of many biotech start-ups hung in the balance and U.S. and European authorities sought to stem contagion to the broader financial sector.
About 40% of the UK's biotech companies, developing drugs for everything from cancer to heart disease, were banking with Silicon Valley Bank's (SVB) British arm, according to the UK BioIndustry Association (BIA).
"This was absolutely crucial for our sector and companies would be going down this morning if there wasn't a solution. On Friday, it was despair. This morning it was elation," said Steve Bates, head of BIA, which represents over 500 companies in the life sciences sector.
Given the time and money required to develop a drug, early-stage biotech firms often operate for years without revenue and depend on start-up friendly banks like SVB for lines of credit to continue their research and development.
SVB UK has loans of around 5.5 billion pounds ($6.66 billion), deposits of about 6.7 billion pounds and about 3,000 UK clients, according to HSBC.
Around 16 tech and life sciences companies in Europe have disclosed about $190 million in exposure to SVB in the United Kingdom and the United States. UK-based companies, including Diaceutics DXRX.L, Ourgene Health Plc YGEN.L and Windward Ltd WNWD.L have said they have exposure to the bank's UK arm.
Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, a NASDAQ-listed but British-headquartered cancer company, suggested that "for smaller private start-ups, SVB was one of the few banks who really understood the risk profile of early stage, venture-backed biotech companies".
Dima Kuzmin, managing partner of London-based investment firm 4BIO Capital, which does not bank with SVB directly but has portfolio companies exposed to the bank, said many entrepreneurs and CEOs of small start-ups had also opened personal accounts with SVB.
"Several CEOs I know and work with have had all of their personal cash with the bank - like literally all of it - because this was their main bank. So you can imagine the scale of anxiety," Kuzmin said.
He said following the sector-saving buyout by HSBC, "concern remains over the potential systemic effects".
Worst case, he said, investors will become more concerned about liquidity in the sector and start drip-feeding the biotechs with smaller funding rounds.
The turmoil follows a difficult year for biotech funding globally. Rising interest rates, recession fears and geopolitical shockwaves saw investors pull back from anything considered risky last year.
In the biotech sector globally, there were only 47 initial public offerings (IPOs) last year that raised about $4 billion in total, compared with 152 offerings in 2021 that had raised over $25 billion.
"And then in 2023, as the market was starting to come back, a shock like this has a chilling effect on the amount of money that would otherwise go into developing new medicines," said James Peyer, CEO of U.S.-based Cambrian Biopharma.
The SVB collapse also comes after the UK's biggest listed drugmakers GSK GSK.L and AstraZeneca AZN.L warned last month that the UK government's ambition to become a life sciences "superpower" has been hampered by a discouraging tax environment among other problems.
Though the country has renowned scientific research centres at Oxford and Cambridge Universities, it has struggled to convert that into a thriving biotech sector attracting the kinds of funds the United States does, experts say.
Coventry-based biotech company NanoSyrinx had 3 to 4 million pounds worth of funds in the UK arm of SVB, and was scrambling on Friday to extract its money, but was unsuccessful in getting a transfer through, founder and CEO Dr. Joe Healey told Reuters.
Ultimately management was reasonably confident that a resolution was going to be found given the government's science superpower agenda meant an intervention was likely, he said.
Going forward, there will likely be more second guessing in the short term for biotech investment in the UK, he added.
"I certainly don't imagine it's going to make securing funds easier for the next couple of years."
($1 = 0.8260 pounds)
FACTBOX-Which companies are affected by SVB collapse?nL4N35L22T
Biden pledges 'whatever needed' for U.S. system as banks hit by SVB fallout nL1N35L0WY
GRAPHIC-SVB collapse a sign of pain coming from end of easy-cash eranL1N35I24C
ANALYSIS-SVB's lightning collapse stuns banking industry nL1N35I2F7
Reporting by Natalie Grover and Maggie Fick in London; Editing by Josephine Mason, Emelia Sithole-Matarise and Christina Fincher
면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.
온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.
이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.